Related Experiment Video
Updated: Jun 22, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Gleason grading controversies: what the chemoprevention trials have taught us
Laurence Klotz1, Darrel Drachenberg, Yves Fradet
1Professor, Department of Surgery, University of Toronto, Toronto, ON;
Abstract:
The recent Prostate Chemoprevention Trial (PCPT), which assessed the efficacy of finasteride in reducing prostate cancer incidence, showed promising results. However, patients who developed cancer had higher Gleason scores than those on placebo. Moreover, recent evidence has shown that the biopsy Gleason scores in patients on finasteride were actually more accurate compared with patients on placebo when matched with the final, radical prostatectomy (RP) scores. This accuracy was due to a reduction in prostate volume induced by the drug, and better performance of prostate-specific antigen correlation for identifying men with high-grade cancer. Re-evaluation of the results based on the pathology of the RP specimens and longer follow-up showed a 30% reduction in cancer incidence with finasteride and no significant differences in Gleason scores compared with placebo.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Cancer Prevention
Some...
Cancer Prevention
Some...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Clinical Trials: Overview
Treatment Resistent Cancers